Time trends in surgical provision and cancer-specific outcomes in patients with stage T2-3 kidney cancer: a
Zhuo Song1, Jizhang Xing2, Zhijia Sun1
1Department of Radiotherapy, Air Force Medical Center, Air Force Medical University, Beijing, China.
Frontiers in Surgery
|May 14, 2024
Summary
Radical nephrectomy remains common for kidney cancer (KC), but partial nephrectomy (PN) is increasingly preferred for T2-3 stages, showing better survival outcomes.
Area of Science:
- Urology
- Surgical Oncology
- Cancer Research
Background:
- Surgery is the primary treatment for kidney cancer (KC).
- Limited guidance exists for surgical decisions in T2-3 stage KC.
- Understanding surgical trends and outcomes is crucial for patient survival.
Purpose of the Study:
- To analyze surgical trends for T2-3 kidney cancer.
- To evaluate the effectiveness of different surgical methods.
- To identify optimal surgical decision criteria.
Main Methods:
- Utilized the Surveillance, Epidemiology, and End Results (SEER) dataset.
- Examined trends in surgical methods and cancer-specific risk of death (CSRD).
- Performed survival rate analysis, including stratification for partial nephrectomy (PN).
Main Results:
- Partial nephrectomy (PN) adoption increased by 7.0% annually.
- PN was associated with more favorable CSRD compared to radical nephrectomy (RN).
- Patients undergoing PN showed improved survival trends.
Conclusions:
- Radical nephrectomy (RN) is still the most frequent surgery for KC.
- There is a growing preference for PN in T2-3 KC.
- PN demonstrates more favorable survival outcomes, warranting further research.
Related Concept Videos
01:21Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K